Introduction Gut microbiota can significantly affect the effectiveness of immune checkpoint
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …

Background Immune checkpoint inhibitors (ICIs) have considerably improved patient
outcomes in various cancer types, but their efficacy remains poorly predictable among …

Simple Summary Proton pump inhibitors (PPIs) are the most commonly used gastric acid
suppressants in cancer patients. However, long-term use of PPIs can cause dysbiosis effects …

Aim: To validate a 'drug score'that stratifies patients receiving immunotherapy based on
concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial …

The management of advanced (locally advanced or metastatic) urothelial carcinoma has
been revolutionized since pembrolizumab was introduced in 2017. Several prognostic …

Context Antibiotics have been suggested to diminish the efficacy of immune checkpoint
inhibitors (ICIs) by alterations of the gut microbiota. Objective To perform a meta-analysis …

Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising
performance in improving the prognosis of urological cancer patients. The goal of this meta …

Objectives We clarified the effect of concomitant proton pump inhibitor use on oncological
outcomes in patients with advanced urothelial carcinoma treated either with chemotherapy …

Background Concomitant medications may potentially affect the outcome of cancer patients.
In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess …

Background While concomitant medications can affect the efficacy of immune checkpoint
inhibitors (ICIs), few studies have assessed associations of concomitant medications with …